secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACHIEVE LIFE SCIENCES, INC. (ACHV)
CIK:        0000949858
Form:       8-K
Filed at:   2022-08-11T23:59:59+00:00
Accession:  0001564590-22-029119
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Achieve Life Sciences Q2 net loss $10.5M; Phase 3 success and $2.5M NIH grant
-----------------------------------------------------------------------------

- Q2 2022 net loss of $10.5M; operating expenses $10.1M; cash & restricted cash $29.4M as of June 30.
- Phase 3 ORCA-2 trial in 810 smokers: 6–8x increased odds of smoking abstinence vs placebo (statistically significant).
- Awarded $2.5M NIH grant for Phase 2 ORCA-V1 trial evaluating cytisinicline in e-cigarette users; trial initiated.
- ORCA-3, the final NDA-enabling smoking cessation trial, continues enrolment.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/949858/000156459022029119/0001564590-22-029119-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/949858/000156459022029119/achv-8k_20220811.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-029119

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer